Leaderboards/Cystic Fibrosis Research Advances

Cystic Fibrosis Research Advances

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Papers

Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity

Cell Metabolism|2024

124 cit.

International disparities in diagnosis and treatment access for cystic fibrosis

Pediatric Pulmonology|2024

70 cit.

Publication in mBio (2024) [57 citations, W4390617450]

mBio|2024

57 cit.

Airway “Resistotypes” and Clinical Outcomes in Bronchiectasis

American Journal of Respiratory and Critical Care Medicine|2024

33 cit.

The structures of protein kinase A in complex with CFTR: Mechanisms of phosphorylation and noncatalytic activation

Proceedings of the National Academy of Sciences|2024

19 cit.

Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation

Cell Host & Microbe|2025

18 cit.

Effect of Weight Loss on Skeletal Muscle Bioactive Lipids in People With Obesity and Type 2 Diabetes

Diabetes|2024

14 cit.

ACE-tRNAs are a platform technology for suppressing nonsense mutations that cause cystic fibrosis

Nucleic Acids Research|2025

12 cit.

Targeting respiratory microbiomes in COPD and bronchiectasis

Expert Review of Respiratory Medicine|2024

11 cit.

Strategies used to access CFTR modulators in countries without reimbursement agreements

Journal of Cystic Fibrosis|2025

10 cit.

Emerging Leaders

Drafting the new consensus

Researchers

Christof J. Majoor

Amsterdam Neuroscience

Jennifer L. Taylor‐Cousar

National Jewish Health

Shen-Yin Zhang

Unknown

Dimitri Declercq

Ghent University Hospital

Sue Wolfe

Leeds Teaching Hospitals NHS Trust

Simon Tian

Vertex Pharmaceuticals (United States)

Deepika Polineni

Washington University in St. Louis

Alexander Elbert

University of Haifa

Andrew Hill

University of Liverpool

Dale Muzzey

Myriad Genetics

Papers

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Journal of Cystic Fibrosis|2022

376 cit.

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study

Journal of Cystic Fibrosis|2023

128 cit.

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

The Lancet Respiratory Medicine|2022

126 cit.

Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design

BMJ Open Respiratory Research|2022

72 cit.

A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators

Pediatric Pulmonology|2022

37 cit.

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Maternal Outcomes During and After Pregnancy

CHEST Journal|2024

21 cit.

Parenthood impacts short-term health outcomes in people with cystic fibrosis

Journal of Cystic Fibrosis|2022

17 cit.

The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis

Clinical Therapeutics|2023

14 cit.

Objective and patient‐based measures of chronic rhinosinusitis in people with cystic fibrosis treated with highly effective modulator therapy

International Forum of Allergy & Rhinology|2022

13 cit.

A provider survey assessing fetal impact of CFTR modulator use in males with CF during assisted and unassisted reproduction and partner pregnancy

Journal of Cystic Fibrosis|2023

9 cit.

Current Senior Leaders

Wrote the book, still writing it

Papers

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

Science|1989

7.4k cit.

Impairment of the Ubiquitin-Proteasome System by Protein Aggregation

Science|2001

2.2k cit.

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

New England Journal of Medicine|2011

2.2k cit.

Aggresomes: A Cellular Response to Misfolded Proteins

The Journal of Cell Biology|1998

2.2k cit.

Cellular and Molecular Barriers to Gene Transfer by a Cationic Lipid

Journal of Biological Chemistry|1995

1.4k cit.

Degradation of CFTR by the ubiquitin-proteasome pathway

Cell|1995

1.3k cit.

Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis

New England Journal of Medicine|1999

1.3k cit.

Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

Nature|1992

1.2k cit.

Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity

Science|1991

1.1k cit.

CFTR as a cAMP-Dependent Regulator of Sodium Channels

Science|1995

1.1k cit.

Reagents for Cystic Fibrosis Research Advances

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

GATA-1 (D24E4) Rabbit Monoclonal Antibody (BSA and Azide Free)

Cited in 8 papers

#27425$865

View Evidence →

Cell Signaling TechnologyEvidence 64

Procaspase Antibody Sampler Kit

Cited in 6 papers

#12742$650

View Evidence →

Cell Signaling TechnologyEvidence 65

NUP98 (C39A3) Rabbit Monoclonal Antibody (Alexa Fluor® 555 Conjugate)

Cited in 5 papers

#20280$465

View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

beta2-microglobulin (F4S6H) Rabbit Monoclonal Antibody

Anti-Cystic Fibrosis Transmembrane Conductance Regulator, a.a. 1370-1380, clone M3A7

Cited in 10 papers

#MAB3480

View Evidence →

Cell Signaling TechnologyEvidence 66

Phospho-Vimentin (Ser56) (D5H2) Rabbit Monoclonal Antibody (BSA and Azide Free)

Cited in 8 papers

#18830$898

View Evidence →